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| INTRODUCTION
The high prevalence of food allergy is now an emerging global public health concern. 1 Estimates of the prevalence of food allergy vary, but overall lifetime prevalence has been estimated to be between 4% and 7% for children and between 3% and 6% for adults in economically developed countries. 2, 3 The quality of life of patients with food allergy is often severely affected, resulting in considerable morbidity and healthcare utilization, including risk of accidental exposure leading to life-threatening anaphylactic reactions. 4 An accurate diagnosis of food allergy is essential to provide appropriate, potentially life-saving advice on how to prevent and manage allergic reactions and prevent unnecessary dietary restrictions. 1, 4 The diagnosis of food allergy is dependent on a thorough clinical history as well as an objective marker of allergic sensitization and, in some cases, oral food challenge tests. 5 Current first-line tests to assess allergen sensitization are skin prick tests (SPT) and/or immunoassays of serum food-specific IgE (sIgE) levels. However, these approaches have a high rate of false-positive results and are poor predictors of the severity of allergic reactions. 4 Thus, diagnostic confirmation with (ideally) a double-blinded placebo-controlled food challenge (DBPCFC) is often required. 5 While DBPCFCs are considered the gold standard diagnostic tests, they are costly, technically challenging, time-consuming, labor-intensive, and are associated with important safety risks, as they can trigger anaphylactic reactions. 4 Given the limitations of conventional methods for diagnosing food allergy, new molecular-based diagnostic techniques-collectively referred to as component-resolved diagnostics (CRD)-have emerged as promising diagnostic tools. 6 While current approaches evaluate patients' reactivity to whole food extracts, CRD involves detecting sIgE levels to individual allergenic molecules or the epitopes of those allergens. 7 This approach may enhance determination of specific food allergy phenotypes, assist in the development of patient-tailored risk profiles for specific food allergens, and improve detection of possible cases of cross-reactivity between different allergenic molecules. 8 Over the last decade, researchers have compared CRD to conventional diagnostic approaches for food allergy. 9 Through this work, the major allergen components in different food allergies have been identified. However, the diagnostic accuracy of identified components varies across studies, and thus, the diagnostic value and clinical utility of CRD remains unclear. 9, 10 CRD approaches are also expensive, which raises questions about their cost-effectiveness. 11 While the diagnostic accuracy of various tests for food allergy was evaluated in our previous systematic review, CRD was not included. 12 A health technology assessment was carried out to evaluate multiplex CRD assays, but clinical effectiveness (rather than diagnostic accuracy) was investigated. 13 To the best of our knowledge, only one CRD-specific diagnostic test accuracy (DTA) review has been conducted, but it focused solely on peanut allergy diagnosis. 14 This review concluded that Ara h 2 showed superior diagnostic accuracy than SPT and sIgE tests, and therefore has the potential to replace first-line tests for the diagnosis of peanut allergy. Given the increasing body of work, there is a need to undertake a more comprehensive evidence synthesis on the diagnostic accuracy of CRD.
We therefore conducted a systematic review to: (i) determine the accuracy of CRD for the diagnosis of food allergy, focusing on the "big eight" food allergies (ie, cow's milk, wheat, hen's egg, peanut, soy, tree nuts, fish, and shellfish allergy); (ii) estimate the effectiveness and cost-effectiveness of CRD in comparison with conventional techniques for the diagnosis of these food allergies; and (iii) summarize the evidence on the ability of CRD to predict the severity of allergic reactions. We focused on these eight food allergies to align with the foods considered in our previous systematic reviews for the European Academy of Allergy and Clinical Immunology.
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| METHODS
The Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) checklist guided the reporting of this systematic review (see Table S1 ). 15 Our protocol was published 16 and preregistered (PROSPERO:CRD42016053512).
| Eligibility criteria
We included prospective, retrospective, cross-sectional, and case-control studies that examined the accuracy of CRD in diagnosing cow's milk, hen's egg, wheat, soybean, peanut, tree nuts, fish, or shellfish allergy in children or adults. Studies were required to have sufficient data to calculate the following four relevant diagnostic measures: sensitivity, specificity, positive predicted value (PPV), and negative predictive value (NPV). Additionally, all studies were required to have a defined study population with either consecutive or random sampling of participants. Studies in which the recruitment technique used to select participants was not indicated were included, and the lack of information regarding their sampling methodology was noted during the quality assessment process. The reference standard was DBPCFC used in at least 50% of the participants.
| Search strategy
Although CRD methods were originally described in the 1990s, 17 their application to food allergy diagnosis was not clinically imple- (Table S2) . We also contacted international experts who have published in the field, screened the references cited in identified studies, and used the citation-tracking feature of Google Scholar to find any additional studies. The list of contacted experts can be found in the online supplement (Table S3) . 
| Study selection and data collection
Two reviewers (JFK and NM) independently screened titles and abstracts and then reviewed full-texts to identify eligible studies.
Authors of studies for which further details were required to determine inclusion or exclusion were contacted to obtain further information to enable a decision. For papers in languages other than English, speakers of the language in question were contacted to determine eligibility. Both reviewers independently extracted data from included studies using a form developed specifically for this systematic review. Study characteristics, DTA measures (ie, sensitivity, specificity, PPV and NPV), and 2 9 2 contingency tables (reflecting the number of true positives, true negatives, false positives, and false negatives) were extracted. DTA measures and 95% confidence intervals were calculated from 2 9 2 contingency tables when not provided by authors. [18] [19] [20] The two reviewers assessed the quality of the included studies using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. 21 Discrepancies were resolved by discussion and consensus, or when necessary, arbitrated by a third reviewer (BN).
| Data synthesis, analysis, and reporting
Diagnostic accuracy measures (sensitivity, specificity, PPV, and NPV) of individual studies were summarized in tables and presented by allergy type and individual allergen component. We had planned to conduct meta-analyses of the evidence with respect to each allergen component by fitting a bivariate model (when included studies used a common threshold) or a hierarchical summary receiver operating characteristic (HSROC) model (when included studies used multiple thresholds). However, we were unable to do this, as the number of studies for each component was too small to permit quantitative syntheses. In a simulated analysis based on the Bayesian approach, it was recommended that a minimum of four studies were required to reasonably fit these models. 22 In a very few cases, we had a maximum of three studies per allergen component; the most common was two studies. The statistical programs we tried to use to fit the models (R and Stata) indicated that the models lacked convergence, as a result of containing too few studies. For these reasons, we narratively synthesized the evidence.
| RESULTS
| Study selection
A total of 10 380 articles were identified through the literature search carried out on June 15, 2016. After excluding duplicate articles, 6853 titles and abstracts were screened against the inclusion and exclusion criteria; of these, 195 full-text papers were assessed. Thirteen articles reporting 11 studies met our criteria and were thus included. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Additionally, one potentially relevant ongoing clinical trial was found in ClinicalTrials.gov (details can be found in Table S4 ). The literature search was updated on February 9, 2017, to incorporate newly published papers. No additional relevant studies were identified in the updated search. The study screening and selection processes are summarized in Figure 1 . A list of potentially relevant studies can be found in the Online supplement (Tables S5   and S6 ). The authors of these studies did not reply to a request for further information. Table 1 includes a summary of the QUADAS-2 quality assessment for each study. Table S7 in the supplementary information provides the detailed QUADAS-2 assessments.
| Characteristics of included studies
| Quality assessment of included studies
| Patient selection
Two studies were rated as high risk of bias (ROB) in this domain because of the use of a case-control design. 32 
| Index test
Two studies had high ROB in this domain because they did not use prespecified thresholds for determining positive results. 27, 33 Eight studies had unclear ROB because they did not report whether index test results were interpreted without knowledge of DBPCFC results. [23] [24] [25] [26] 28, 31, 32, 34 Only one study had low ROB in this domain. 30 Two studies used immunoblotting assays to analyze sIgE reactivity against allergens; because these assays do not provide quantitative sIgE levels, these two studies were scored as unsure in terms of their applicability to this review's research question.
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| Reference standard
One study did not specify the criteria used to classify DBPCFC results and was thus scored as having an unclear ROB in this domain. 26 Two studies were scored as unsure in terms of their applicability to this review's research question. 30, 32 The reason for this appraisal was that the purpose of this review was to assess the accuracy of CRD and its ability to predict allergy severity (both of which are assessed through objective symptoms in a DBPCFC), and the two aforementioned studies included patients with mild or subjective DBPCFC symptoms in the same group as patients with negative DBPCFC.
| Patient flow and timing
Two studies had a high ROB in this domain because less than 100% of patients underwent DBPCFCs, and not all patient data were included in their data analysis. 26, 34 Three studies specified the time interval between index and reference tests, compared all patients against the same reference standard, included all patients in data analysis, and were thus ranked as low ROB in this domain. 24, 25, 27 The remaining six studies failed to meet at least one of those criteria and were thus scored as having an unclear ROB. 
| Hen's egg allergy
Three studies evaluated CRD for hen's egg allergy, 24, 25, 33 and the following components were assessed: Gal d 1 (ovomucoid), Gal d 2 (ovalbumin), Gal d 3 (ovotransferrin), and Gal d 4 (lysozyme). Two studies investigated heated egg and raw egg allergy separately, 24, 25 while the third study analyzed only raw egg allergy. 33 For heated egg allergy, the reported sensitivity-specificity for these components were as follows: and 93.9% (at >0.01 kUa/L). 24 For raw egg allergy, the reported sensitivity-specificity for these components were as follow: and Bet v 2 (profilin) (from the European White Birch) could also predict hazelnut allergy. 32 The reported sensitivity-specificity for these components were as follows: 
| Shrimp allergy
Two studies reported data on CRD for shrimp allergy. 26, 34 One study | 1617 sensitivity-specificity pair of Lit v 1 was 82.8% and 56.3%, and of Lit v 4 was 34.5% and 93.8%, 34 and the reported sensitivity-specificity pair of Pen a 1 was 88.2% and 23.8% (at >0.35 kUa/L). 26 With regards to epitope data, the epitopes with highest DTA were found on Lit v 1 and Lit v 2. 26, 34 Table S8 in the online supplement presents the full DTA data by epitope.
| Cost-effectiveness of CRD
None of the studies meeting our inclusion criteria evaluated the cost-effectiveness of CRD or made mention of any economic considerations. The only relevant evidence identified was two manufacturer-authored abstracts featuring Markov simulation-based costutility models for CRD vs DBPCFC for peanut allergy and one with unspecified methodology featuring multiple food allergies; contacting the authors confirmed there were no accompanying peer-reviewed papers.
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| Risk assessment ability of CRD
Two studies assessing CRD for hen's egg allergy found that sIgE levels for all components tested were higher in patients with more severe allergies. 24, 25 Another study found similar results for cow's milk-allergic patients. 23 For peanut allergy, one study found that patients with more severe food challenge reactions had higher sIgE levels to Ara h 1, 2, 3, and 6 than did patients with no reaction or mild symptoms. 30 Furthermore, this study found that all severe allergic patients were sensitized to Ara h 2 or Ara h 6, and none of them were sensitized to Ara h 1, 3, or 9 without Ara h 2. 30 For hazelnut allergy, one study found that higher sIgE levels to Cor a 9 and Cor a 14 were associated with more severe reactions in food challenges, but found no correlation between sIgE levels to Cor a 1 or Cor a 8 and reaction severity. and 87.5%), 23 Gal d 1 for hen's egg allergy (84.2% and 89.8% for heated egg, and 60.6% and 97.1% for raw egg), 24 Ara h 6 for peanut allergy (94.9% and 95.1%), 30 Cor a 14 for hazelnut allergy (100% and 93.8%), 27 and Lit v 1 for shrimp (82.8% and 56.3%). 34 Additionally, T A B L E 2 (Continued) 71. 4 (35.6-91.9) two studies found that individual epitopes in shrimp's Lit v 1 and Lit v 2 could potentially have high diagnostic accuracy measures. 26, 34 Of the included studies, one study had a high ROB score in two of the four QUADAS-2 domains, 34 and four studies had one such score. 26, 27, 32, 33 The remaining six studies were scored low or unclear ROB in all four domains. [23] [24] [25] 28, 30, 31 
| Strengths and limitations
To the best of our knowledge, this is the first systematic review analyzing the evidence on the diagnostic accuracy of CRD for a range of food allergies. The strengths of this study include the use of a highly sensitive search strategy with no language restrictions, which allowed a comprehensive literature search, conducted across several databases and clinical trial registries. The inclusion criteria for this review were carefully selected to provide clinically relevant information. 16 Similar work in the field, including a RAND report and a systematic review by the European Academy of Allergy and Clinical
Immunology (EAACI) Food Allergy and Anaphylaxis Guidelines
Group, 12, 39 was used as bases for the inclusion criteria of this review.
Furthermore, the internal validity of the studies included in this review was strong, as they all used DBPCFC as the reference standard in at least 50% of participants. A limitation of this review is that due to the large degree of heterogeneity between studies that met the inclusion criteria (in terms of the components tested, the particular CRD assay employed, and the cutoff values used), a quantitative synthesis of data could not be undertaken. Additionally, we acknowledge that food allergies other than the ones we focused on are becoming increasingly important. As our search strategy was broadly formulated, we were, in response to expert peer-review feedback, able to check for any other potentially relevant studies for other foods. We were however unable to find any such studies. In the future, in the context of planned updates to this review, we plan to formally include terms for other foods (eg, apple, cherry, and peach) as this may impact on the sensitivity of our searches.
| Comparison of findings with the wider literature
The results of this review corroborate the findings of a previous DTA systematic review on CRD for peanut allergy, 14 suggesting that sIgE levels to the component Ara h 2 can provide diagnostic measures with very high accuracy. Our review, however, used more rigorous inclusion criteria than the previous one, strengthening the DTA evidence in relation to this component. The studies included in our review that analyzed peanut components also found that sIgE levels to the components Ara h 1, 3, 8, and 9 showed varying results, most with underperforming diagnostic values. 14 Nevertheless, this is the first review to present evidence on the diagnostic value of Ara h 6 as a CRD component, which was found to have higher sensitivity and specificity values than Ara h 2.
When comparing the diagnostic accuracy of CRD found in our review with that of first-line diagnostic tests for food allergy (atopy patch tests (APT), SPT, and sIgE) reported in a previous systematic review, 12 Finally, there is a dearth of evidence on the cost-effectiveness and the risk assessment ability of CRD relative to current care models. In principle, it may be possible to utilize some of the data obtained here for use in economic modeling to facilitate comparisons of the relative value of any trade-off between sensitivity and specificity in a more formal manner. Such analyses were beyond the scope of this review.
| Implications for patient care
Selected CRD components have the potential to diagnose food allergies with a higher specificity, but lower sensitivity than current firstline tests. Furthermore, risk assessments carried out by five of the included studies suggest that quantitative measurements of sIgE levels to key components have the potential to identify patients with more severe allergic phenotypes. Such is the case for Ara h 2 and Ara h 6 for peanut allergy, and Cor a 9 and Cor a 14 for hazelnut allergy. Nevertheless, further research is necessary to draw stronger conclusions and to determine the components with the highest diagnostic value, as well as the clinically appropriate cutoff values.
Importantly, all studies included in this review recruited patients with suspected allergies. Therefore, it is likely that the prevalence of allergies in the study populations is considerably higher than in more population-based settings, rendering the tests' PPVs higher and NPVs lower than they would be in populations with lower allergy prevalence.
| CONCLUSIONS
The findings of this review suggest that some CRD components have the potential to diagnose cow's milk, hen's egg, peanut, hazelnut, and shrimp allergies with high specificity, but low sensitivity.
Nevertheless, at present, there is not enough methodologically robust evidence to draw definite conclusions. Further studies employing DBPCFC as the reference standard are urgently needed to effectively evaluate the DTA and cost-effectiveness of CRD, as well as standardization of the components assessed and CRD assays used, and consensus on study reporting.
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